(Bloomberg) -- Life-sciences company Danaher Corp. has stopped pursuing Catalent Inc. after expressing interest in buying the contract manufacturer, according to people familiar with the matter.
Life-sciences company Danaher Corporation (NYSE: DHR) is reportedly no longer considering a takeover of contract manufacturer Catalent Inc (NYSE: CTLT) after expressing interest in buying the ...
But there are also those other two issues. Danaher was said to be pursuing Catalent for a takeover at significantly above the then price of $70 per share (about). Then came the report of the ...
Days later, Bloomberg reported that Danaher Corp. was no longer considering a takeover of Catalent, according to people familiar with the situation. Danaher had earlier made overtures to the ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want ...
See: Catalent stock rockets 21% premarket on report of takeover interest from Danaher And that’s not all. Catalent also saw higher-than-expected costs at a drug product and drug substance ...
Pall Corp. (PLL) stock is rising after the company said it will be acquired by Danaher (DHR) for $13.8 billion. Pall Corp. (PLL) stock is rising after the company said it will be acquired by ...
Wells Fargo's upgrade Tuesday also comes a day after Danaher reportedly ended a potential bid to acquire contract manufacturer Catalent (CTLT), according to Bloomberg, citing people familiar with ...
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...
Maravai LifeSciences Holdings Inc MRVI reportedly attracted takeover interest from Thomas ... appointed William "Trey" Martin III, a former Danaher executive, as its new CEO.
